EXMceuticals Inc. (CSE: EXM)
(FSE: A2PAW2) (the “
Company” or
“
EXM”), a producer of high-grade cannabis
extracted ingredients for the pharmaceutical, nutraceutical,
therapeutical and cosmetic industries, is pleased to announce
the appointment of Michael Kinley CPA,CA to the position of Chief
Financial Officer.
Mr. Kinley, a former partner with KPMG, has been
the President of Winslow Associates Management & Communications
Inc. since 1993, a private consulting firm which provides
professional services to junior public companies. Mr. Kinley is a
Chartered Professional Account and has served as an officer and
director for several public companies over the past thirty years.
His appointment is effective immediately.
Jonathan Summers, CEO and Chairman of the Board
said: “Mr. Kinley brings with him extensive experience in the
regulatory market and has a long history of leading junior
companies. Mr. Kinley is a great addition to the EXM management
team, and he frankly impressed us from our first conversation. I am
pleased to welcome Michael as permanent CFO and I am looking
forward to working with him on executing our strategy in becoming a
leading low-cost producer of high-quality cannabis and hemp
ingredients for the European and North American markets.”
Additionally, EXM and the minority shareholders
of EXMceuticals Portugal, Lda (“EXM Portugal”),
have signed an agreement, under the terms of which EXM has acquired
the minority stake (30% of EXM Portugal) for its nominal value. As
a result of the acquisition of EXM Portugal at the present date,
EXM holds, directly and indirectly, 100% of the share capital of
EXM Portugal. EXM Portugal is the entity that holds a licence
for cannabis research and development issued by INFARMED, the
Portuguese National Authority of Medicines and Health Products.
This license authorizes the Company to import, research and refine
cannabinoids and cannabis by-products in Portugal. EXM Portugal
operates a state-of-the-art pilot-scale refinery in Portugal for
the transformation of cannabis-based ingredients on a R&D
environment and conditions. EXM also owns 100% of the share capital
of EXMceuticals Portugal II Lda (“EXM Portugal
II”), which is the industrial company currently finalising
the internal design and equipment plans for the factory building
located in Setubal, just south of Lisbon. The EXM Portugal II
facility will consist of both extraction and refining
installations, be designed and operated to GMP standards, and once
licensed will distribute pure cannabinoids to commercial
buyers.
The Company also announces that it has granted
incentive stock options to a director of the Company to purchase up
to an aggregate of 466,931 common shares of the Company pursuant to
the Company’s Omnibus Equity Compensation Plan (the
“Plan”). The stock options are exercisable at a
price of $2.00 per share for a period of 10 years from the date of
grant. The Company has also issued an aggregate of 2,250,000
restricted share units (“RSUs”) under the Plan to
executive officers of the Company. The RSUs have a deemed price of
$0.50 per unit and entitle the holder to receive one share of the
Company per RSU, subject to vesting in equal annual instalments
over a three-year period.
ON BEHALF OF THE BOARD OF DIRECTORS OF
EXMCEUTICALS INC.
Jonathan Summers, Chairman and Chief Executive
Officer
For further information contact: Investor
Relations Email: investors@exmceuticals.com
Media
Enquiries:Email: media@exmceuticals.com Mélanie Guillemette:
+1 819 668 2734
FOR MORE UPDATES ON THE
COMPANY
Follow us on Twitter:
https://twitter.com/EXMceuticals
Follow us on LinkedIn:
https://www.linkedin.com/company/exmceuticalsinc/
ABOUT EXMCEUTICALS
EXM is targeting the wellness and medical
applications of cannabis. EXM’s activities are focused on the
sustainable cultivation of cannabis and hemp, and the production of
high-grade cannabis and hemp ingredients for the pharmaceutical,
therapeutical, nutraceutical and cosmetic industries. The Company
proposes to sell the produced ingredients to international markets.
EXM is not a recreational cannabis company.
EXM was recently granted the required
authorizations and permits in Portugal for its existing laboratory
and pilot refinery for cannabis research. EXM has previously
completed research projects with its university partners,
Universidade Nova de Lisboa and Universidade Lusofona as well as
applying for P2020 research grants. Following receipt of these
unique Portuguese cannabis authorizations and permits, EXM is
proceeding with its planned R&D program, lab work and testing.
In addition to this more scientific mandate, EXM is now projecting
and building a significantly larger refining facility in Portugal
which once complete and licensed will be used by EXM as its base
for distribution of cannabis ingredients in the EU and North
America.
EXM has also submitted applications and
undertaken negotiations with local governments and partners in
Ethiopia, Malawi, Zambia, Eswatini and Burundi, in order to obtain
licences to permit the cultivation of cannabis and hemp, as well as
the processing, transformation and export of psychotropic and
non-psychotropic cannabinoid ingredients. In Ethiopia, EXM is in
its final stage of negotiation with the government for an
agro-industrial park, of 4,000 hectares (9,880 acres) encompassing
a free trade zone, for which EXM has already obtained land rights
over 2,000 hectares (4,940 acres) in the Amhara region.
CSE: EXM| FSE: A2PAW2
Neither the CSE nor the FSE has approved nor
disapproved the contents of this news release. Neither the CSE nor
the FSE accepts responsibility for the adequacy or accuracy of this
release.
Certain information contained herein may
constitute “forward-looking information” under Canadian securities
legislation. Generally, forward-looking information can be
identified by the use of forward-looking terminology such as, “will
be”, “expected”, “proposes”, “intends” or variations of such words
and phrases or statements that certain actions, events or results
“will” occur. Forward-looking statements regarding the Company’s
business operations, including the cultivation of cannabis in
Ethiopia and elsewhere, the extraction of cannabis ingredients and
the exportation of the extracts, the results of testing at our
facilities established for the European market, future laws and
regulations governing the sale of our products in Europe and
elsewhere, and the potential to generate sales, are subject to
known and unknown risks, uncertainties and other factors that may
cause the actual results, level of activity, performance or
achievements of EXM to be materially different from those expressed
or implied by such forward-looking statements or forward-looking
information. There can be no assurance that such statements will
prove to be accurate, as actual results and future events could
differ materially from those anticipated in such statements.
Accordingly, readers should not place undue reliance on
forward-looking statements and forward-looking information. EXM
will not update any forward-looking statements or forward-looking
information that are incorporated by reference herein, except as
required by applicable securities laws.
EXMceuticals (CSE:EXM)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
EXMceuticals (CSE:EXM)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024